Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 08, 2025 19:45 ET | Source: Nilo Therapeutics

Nilo Therapeutics é lançada com financiamento de US $101 milhões da Série A para promover uma nova classe de medicamentos direcionados a circuitos neurais em doenças imunológicas e nomeia Kim Seth como CEO

NOVA YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- A Nilo Therapeutics, uma empresa de biotecnologia que utiliza circuitos neurais para restaurar a homeostase imunológica em doenças, foi lançada hoje com...
October 08, 2025 19:45 ET | Source: Nilo Therapeutics

ナイロ・セラピューティクス (Nilo Therapeutics)、免疫疾患における神経回路を標的とする新しい種類の医薬品開発を推進するため、1億100万米ドル (約154億1,290万円) のシリーズA資金調達を実施し、キム・セス博士 (Kim Seth, Ph.D.) を最高経営責任者 (CEO) に任命

ニューヨーク発, Oct. 09, 2025 (GLOBE NEWSWIRE) -- 神経回路を活用して疾患における免疫恒常性を回復させるバイオテクノロジー企業であるナイロ・セラピューティクスは本日、ザ・カラム・グループ (TCG)、DCVCバイオ、ラックス・キャピタルが主導し、ゲイツ財団およびアレクサンドリア・ベンチャー・インベストメンツが参加する1億100万米ドル...
October 08, 2025 07:09 ET | Source: Nilo Therapeutics

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer

Nilo Therapeutics launches with $101 million Series A to target neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer